Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Coffee consumption and the risk of malignant melanoma in the Norwegian Women and Cancer (NOWAC) Study

Authors: Marko Lukic, Mie Jareid, Elisabete Weiderpass, Tonje Braaten

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Coffee contains biologically-active substances that suppress carcinogenesis in vivo, and coffee consumption has been associated with a lower risk of malignant melanoma. We studied the impact of total coffee consumption and of different brewing methods on the incidence of malignant melanoma in a prospective cohort of Norwegian women.

Methods

We had baseline information on total coffee consumption and consumption of filtered, instant, and boiled coffee from self-administered questionnaires for 104,080 women in the Norwegian Women and Cancer (NOWAC) Study. We also had follow-up information collected 6–8 years after baseline. Multiple imputation was used to deal with missing data, and multivariable Cox regression models were used to calculate hazard ratios (HR) for malignant melanoma by consumption category of total, filtered, instant, and boiled coffee.

Results

During 1.7 million person-years of follow-up, 762 cases of malignant melanoma were diagnosed. Compared to light consumers of filtered coffee (≤1 cup/day), we found a statistically significant inverse association with low-moderate consumption (>1–3 cups/day, HR = 0.80; 95 % confidence interval [CI] 0.66–0.98) and high-moderate consumption of filtered coffee (>3–5 cups/day, HR = 0.77; 95 % CI 0.61–0.97) and melanoma risk (ptrend = 0.02). We did not find a statistically significant association between total, instant, or boiled coffee consumption and the risk of malignant melanoma in any of the consumption categories.

Conclusions

The data from the NOWAC Study indicate that a moderate intake of filtered coffee could reduce the risk of malignant melanoma.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
Cancer in Norway 2013 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015.
3.
Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71–83.CrossRefPubMed
4.
Bohn SK, Blomhoff R, Paur I. Coffee and cancer risk, epidemiological evidence, and molecular mechanisms. Mol Nutr Food Res. 2014;58(5):915–30.CrossRefPubMed
5.
Parras P, Martinez-Tome M, Jimenez AM, Murcia MA. Antioxidant capacity of coffees of several origins brewed following three different procedures. Food Chem. 2007;102(3):582–92.CrossRef
6.
Sanchez-Gonzalez I, Jimenez-Escrig A, Saura-Calixto F. In vitro antioxidant activity of coffees brewed using different procedures (Italian, espresso and filter). Food Chem. 2005;90(1–2):133–9.CrossRef
7.
Wu HT, Reeves KW, Qian J, Sturgeon SR. Coffee, tea, and melanoma risk among postmenopausal women. Eur J Cancer Prev. 2015;24(4):347–52.CrossRefPubMed
8.
Loftfield E, Freedman ND, Graubard BI, Hollenbeck AR, Shebl FM, Mayne ST, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst. 2015;107(2):dju421.CrossRefPubMedPubMedCentral
9.
Wu SW, Han JL, Song FJ, Cho EY, Gao X, Hunter DJ, et al. Caffeine intake, coffee consumption, and risk of cutaneous malignant melanoma. Epidemiology. 2015;26(6):898–908.CrossRefPubMedPubMedCentral
10.
Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer. 1997;71(4):600–4.CrossRefPubMed
11.
Yew YW, Lai YC, Schwartz RA. Coffee consumption and melanoma: a systematic review and meta-analysis of observational studies. Am J Clin Dermatol. 2015;17(2):113-23.
12.
Wang J, Li X, Zhang D. Coffee consumption and the risk of cutaneous melanoma: a meta-analysis. Eur J Nutr. 2015.
13.
14.
Lund E, Dumeaux V, Braaten T, Hjartaker A, Engeset D, Skeie G, et al. Cohort profile: the Norwegian women and cancer study--NOWAC--Kvinner og kreft. Int J Epidemiol. 2008;37(1):36–41.CrossRefPubMed
15.
Hjartaker A, Andersen LF, Lund E. Comparison of diet measures from a food-frequency questionnaire with measures from repeated 24-hour dietary recalls. The Norwegian Women and Cancer Study. Public Health Nutr. 2007;10(10):1094–103.CrossRefPubMed
16.
Hu FB, Stampfer MJ, Rimm E, Ascherio A, Rosner BA, Spiegelman D, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol. 1999;149(6):531–40.CrossRefPubMed
17.
Lozcano-Ponce E. Second expert report, food, nutrition, physical activity and the prevention of cancer: a global perspective. Salud Publica Mexico. 2009;51:S678–80.CrossRef
18.
Veierod MB, Weiderpass E, Thorn M, Hansson J, Lund E, Armstrong B, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst. 2003;95(20):1530–8.CrossRefPubMed
19.
Lee PY, Silverman MK, Rigel DS, Vossaert KA, Kopf AW, Bart RS, et al. Level of education and the risk of malignant-melanoma. J Am Acad Dermatol. 1992;26(1):59–63.CrossRefPubMed
20.
Lee TK, MacArthur AC, Gallagher RP, Elwood MJ. Occupational physical activity and risk of malignant melanoma: the Western Canada Melanoma Study. Melanoma Res. 2009;19(4):260–6.CrossRefPubMed
21.
Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Cause Control. 2003;14(9):847–57.CrossRef
22.
Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br Med J. 2009;339.
23.
White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99.CrossRefPubMed
24.
Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91(434):473–89.CrossRef
25.
Lund E, Kumle M, Braaten T, Hjartaker A, Bakken K, Eggen E, et al. External validity in a population-based national prospective study--the Norwegian Women and Cancer Study (NOWAC). Cancer Causes Control. 2003;14(10):1001–8.CrossRefPubMed
26.
Veierod MB, Adami HO, Lund E, Armstrong BK, Weiderpass E. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev. 2010;19(1):111–20.CrossRefPubMed
27.
Nilsson LM, Johansson I, Lenner P, Lindahl B, Van Guelpen B. Consumption of filtered and boiled coffee and the risk of incident cancer: a prospective cohort study. Cancer Causes Control. 2010;21(10):1533–44.CrossRefPubMed
28.
Stensvold I, Jacobsen BK. Coffee and cancer - a prospective-study of 43,000 Norwegian men and women. Cancer Cause Control. 1994;5(5):401–8.CrossRef
29.
30.
Liu JB, Shen B, Shi MX, Cai J. Higher caffeinated coffee intake is associated with reduced malignant melanoma risk: a meta-analysis study. PLoS One. 2016;11(1):e0147056.CrossRefPubMedPubMedCentral
31.
Gaascht F, Dicato M, Diederich M. Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer. Genes Nutr. 2015;10(6):1–17.CrossRef
32.
Lu Y-P, Lou Y-R, Xie J-G, Peng Q-Y, Liao J, Yang CS, et al. Topical applications of caffeine or (−)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci U S A. 2002;99(19):12455–60.CrossRefPubMedPubMedCentral
33.
Lou YR, Peng QY, Li T, Nolan B, Bernard JJ, Wagner GC, et al. Oral caffeine during voluntary exercise markedly inhibits skin carcinogenesis and decreases inflammatory cytokines in UVB-treated mice. Nutr Cancer. 2013;65(7):1002–13.CrossRefPubMed
34.
Conney AH, Lou YR, Nghiem P, Bernard JJ, Wagner GC, Lu YP. Inhibition of UVB-induced nonmelanoma skin cancer: a path from tea to caffeine to exercise to decreased tissue fat. Top Curr Chem. 2013;329:61–72.CrossRefPubMedPubMedCentral
35.
Bakuradze T, Parra GAM, Riedel A, Somoza V, Lang R, Dieminger N, et al. Four-week coffee consumption affects energy intake, satiety regulation, body fat, and protects DNA integrity. Food Res Int. 2014;63(Part C):420–7.CrossRef
36.
Winkler S, Dieminger N, Blust V, Riedel A, Bakuradze T, Montoya G, et al. Modulation of inflammatory gene transcription after long-term coffee consumption. Food Res Int. 2014;63(Part C):428–38.CrossRef
37.
Kyrgidis A, Tzellos T-G, Triaridis S. Melanoma: stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinogenesis. 2010;9:3.CrossRef
Metadata
Title
Coffee consumption and the risk of malignant melanoma in the Norwegian Women and Cancer (NOWAC) Study
Authors
Marko Lukic
Mie Jareid
Elisabete Weiderpass
Tonje Braaten
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2586-5

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Case report

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

Research article

Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis

Research article

Tumor characteristics and prognosis in familial breast cancer

Research article

Risk factors for cancer development in type 2 diabetes: A retrospective case-control study

Research article

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

Research article

Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits